ESMO Congress
Trastuzumab Deruxtecan Therapy for Colorectal Cancer Yields Best Results in Patients with Elevated HER2 Expression
September 27, 2021
Article
Patients with HER2-positive, metastatic colorectal cancer and higher HER2 expression at baseline experienced improved responses following treatment with trastuzumab deruxtecan.
Four-Year Follow-Up Shows Neoadjuvant Carboplatin/Paclitaxel Combo Improves Event-Free Survival in TNBC
September 26, 2021
Article
A 4-year follow-up of patients with treatment-naïve triple-negative breast cancer who received carboplatin plus neoadjuvant paclitaxel, followed by doxorubicin and cyclophosphamide, suggests that the regime induces superior pathological complete response and event-free survival.
Adavosertib Demonstrates Greater Progression-Free Survival in RAS-/TP53-Mutant Metastatic Colorectal Cancer
September 25, 2021
Article
Adavosertib decreased the risk of disease progression or death by 65% in patients with TP53-/RAS-mutant metastatic colorectal cancer (mCRC).
Balstilimab Zalifrelimab Combination Yields Promising Results in Recurrent/Metastatic Cervical Cancer
September 23, 2021
Article
A phase 2 trial presented at the 2021 ESMO Annual Congress showed that Balstilimab plus Zalifrelimab induced superior response rates, duration of responses, and overall survival in patients with recurrent/metastatic cervical cancer.
UK Study of Real-World Data Shows Survival Benefit of Cabozantinib vs Axitinib in Pre-Treated RCC
September 21, 2021
Article
Patients with advanced RCC who received prior VEGF-targeted therapy tend to have longer survival outcomes with cabozantinib than with axitinib.
Rechallenge With Olaparib Maintenance Improves PFS in Heavily Pretreated Ovarian Cancer
September 21, 2021
Article
Rechallenge with maintenance olaparib following response to platinum-based chemotherapy significantly improved PFS in heavily pretreated patients with relapsed ovarian cancer.
Tisotumab Vedotin Combinations May Be Associated with Meaningful Responses in Recurrent/Metastatic Cervical Cancer
September 20, 2021
Article
Interim findings presented at the 2021 ESMO congress suggest that tisotumab vedotin plus frontline carboplatin and second-/third-Line pembrolizumab may be a suitable treatment option for recurrent/metastatic cervical cancer.
Global Study Suggests More Informational Resources Needed for Renal Cell Carcinoma
September 19, 2021
Article
A global study revealed that patients and caregivers alike reported insufficient knowledge surrounding renal cell carcinoma.
Study Finds Similar Clinical Characteristics in VHL-Mutated and VHL Wild Type Clear Cell RCC
September 18, 2021
Article
Characteristics such as low positive PD-L1 expression and rare high positive staining were identified in both patients with VHL-mutated and VHL wild type clear cell renal cell carcinoma.
Dostarlimab Elicits Superior Responses in Patients with High Mutational Burden in Endometrial Cancer
September 17, 2021
Article
Patients with endometrial cancer and high tumor mutational burden experienced superior overall response rates to the agent dostarlimab than patients with low mutational burden.